What type of study is this?

This is a Human Clinical Trial study (also classified as: Phase 2).

December 8, 2025Blood

Eltrombopag plus G-CSF for peripheral blood stem cell mobilization: Final analysis of a single arm, Phase 2 trial

View Full Paper

Ask AI

Bookmark

Authors

Phase 2 trial shows added eltrombopag improves PBSC harvest efficiency in lymphoma patients, indicating enhanced outcomes.

Addition of eltrombopag improved PBSC mobilization efficiency, enhancing cell yield for transplantation.
29 of 39 enrolled patients achieved over 2.0 × 106/kg CD34+ cells on the first apheresis day, meeting the primary endpoint.
Phase 2 trial demonstrated safety and efficacy, with adverse events comparable to historical controls and no severe hepatotoxicity.
Potential long-term benefits of the intervention warrant further explorations and confirmatory studies.

Yu et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025Blood

View Full Paper

Ask AI

Bookmark

Authors

Phase 2 trial shows added eltrombopag improves PBSC harvest efficiency in lymphoma patients, indicating enhanced outcomes.

Addition of eltrombopag improved PBSC mobilization efficiency, enhancing cell yield for transplantation.
29 of 39 enrolled patients achieved over 2.0 × 106/kg CD34+ cells on the first apheresis day, meeting the primary endpoint.
Phase 2 trial demonstrated safety and efficacy, with adverse events comparable to historical controls and no severe hepatotoxicity.
Potential long-term benefits of the intervention warrant further explorations and confirmatory studies.

Yu et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark